Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -61.33% is in line with its 5-year average of -59.65%, near the high end of its 5-year range (-888.95%–-30.43%).
As of the fiscal period ended Tuesday, June 30, 2026. 79.77% above its 12-month average of -303.21%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -61.33%.
RETURN ON EQUITY (ROE)
-61.33%
RETURN ON EQUITY (ROE) AVG TTM
-303.21%
RETURN ON EQUITY (ROE) AVG 3Y
-108.69%
RETURN ON EQUITY (ROE) AVG 5Y
-59.65%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+79.77%
CURRENT VS 3Y AVG
+43.57%
CURRENT VS 5Y AVG
-2.83%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-41.20%
median of 733 covered companies
CURRENT VS SECTOR MEDIAN
-48.86%
vs the sector median at left
Spruce Biosciences, Inc.
Market Cap
$119.56M
Return on Equity (ROE)
-61.33%
TTM Avg
-303.21%
3Y Avg
-108.69%
5Y Avg
-59.65%
Market Cap
$119.26M
Return on Equity (ROE)
-5.10%
TTM Avg
-4.24%
3Y Avg
-6.16%
5Y Avg
0.09%
Market Cap
$120.35M
Return on Equity (ROE)
-148.56%
TTM Avg
-96.59%
3Y Avg
-83.25%
5Y Avg
-64.44%
Market Cap
$120.92M
Return on Equity (ROE)
-2.13%
TTM Avg
-45.09%
3Y Avg
-61.80%
5Y Avg
-44.27%
Market Cap
$121.37M
Return on Equity (ROE)
-663.38%
TTM Avg
-427.48%
3Y Avg
-294.92%
5Y Avg
-251.31%
Market Cap
$121.78M
Return on Equity (ROE)
-30.12%
TTM Avg
-27.41%
3Y Avg
-24.34%
5Y Avg
-19.85%
Market Cap
$117.31M
Return on Equity (ROE)
-57.47%
TTM Avg
-26.63%
3Y Avg
16.73%
5Y Avg
210.40%
Market Cap
$121.95M
Return on Equity (ROE)
-165.57%
TTM Avg
-146.09%
3Y Avg
30.63%
5Y Avg
465.14%
Market Cap
$115.76M
Return on Equity (ROE)
-0.05%
TTM Avg
-43.47%
3Y Avg
9.13%
5Y Avg
-18.50%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Spruce Biosciences, Inc. (SPRB) | $119.56M | -61.33% | -303.21% | -108.69% | -59.65% |
| BGM Group Ltd. (BGM)vs › | $119.26M | -5.10% | -4.24% | -6.16% | 0.09% |
| Tenaya Therapeutics, Inc. (TNYA)vs › | $120.35M | -148.56% | -96.59% | -83.25% | -64.44% |
| enGene Holdings Inc. (ENGN)vs › | $120.92M | -2.13% | -45.09% | -61.80% | -44.27% |
| Cibus, Inc. (CBUS)vs › | $121.37M | -663.38% | -427.48% | -294.92% | -251.31% |
| Seer, Inc. (SEER)vs › | $121.78M | -30.12% | -27.41% | -24.34% | -19.85% |
| LENZ Therapeutics, Inc. (LENZ)vs › | $117.31M | -57.47% | -26.63% | 16.73% | 210.40% |
| TuHURA Biosciences, Inc. (HURA)vs › | $121.95M | -165.57% | -146.09% | 30.63% | 465.14% |
| Coya Therapeutics, Inc. (COYA)vs › | $115.76M | -0.05% | -43.47% | 9.13% | -18.50% |
| Genelux Corporation (GNLX)vs › | $114.57M | -209.73% | -196.07% | -130.72% | -67.26% |
ROE
-61.3%
ROA
-49.9%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -61.33% |
| 2026-03-31 | -107.34% |
| 2025-12-31 | -91.65% |
| 2025-09-30 | -888.95% |
| 2025-06-30 | -366.75% |
| 2025-03-31 | -361.86% |
| 2024-12-31 | -184.02% |
| 2024-09-30 | -76.35% |
| 2024-06-30 | -72.86% |
| 2024-03-31 | -70.17% |
| 2023-12-31 | -62.63% |
| 2023-09-30 | -57.52% |
| 2023-06-30 | -49.88% |
| 2023-03-31 | -43.71% |
| 2022-12-31 | -67.43% |
| 2022-09-30 | -56.35% |
| 2022-06-30 | -49.67% |
| 2022-03-31 | -44.06% |
| 2021-12-31 | -37.97% |
| 2021-09-30 | -34.62% |
| 2021-06-30 | -30.43% |
| 2021-03-31 | -24.34% |
| 2020-12-31 | -19.77% |
| 2020-06-30 | -59.11% |
